Compare Stocks → Central Banks Preparing for US Dollar Collapse? (From Behind the Markets) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:NBSENASDAQ:NEPTNASDAQ:PHASNASDAQ:VYNE Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeNBSENeuBase Therapeutics$0.45+3.5%$0.78$0.40▼$5.40$1.68M0.88239,370 shs284,674 shsNEPTNeptune Wellness Solutions$0.43$0.19▼$28.00$906K2.19462,687 shs2.25 million shsPHASPhaseBio Pharmaceuticals$0.00$0.07▼$4.08$3.50M2.57848,888 shs2,910 shsVYNEVYNE Therapeutics$3.07+3.7%$2.16$1.67▼$8.73$43.29M1.18137,814 shs294,678 shsThe 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceNBSENeuBase Therapeutics+3.50%-56.32%-50.60%-39.21%-87.49%NEPTNeptune Wellness Solutions0.00%0.00%-51.22%-62.43%-99.00%PHASPhaseBio Pharmaceuticals0.00%0.00%0.00%-98.57%+25.00%VYNEVYNE Therapeutics+3.72%+31.76%+29.54%+31.76%+18.30%Your $200 account credit is about to expire (Ad)Update to MarketBeat All Access and Save $300 on Your Annual SubscriptionStart Your Risk-Free Trial HereMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationNBSENeuBase Therapeutics1.6548 of 5 stars0.05.00.04.61.90.80.6NEPTNeptune Wellness Solutions0.2313 of 5 stars0.03.00.00.01.90.80.6PHASPhaseBio PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AVYNEVYNE Therapeutics3.8298 of 5 stars3.55.00.00.03.91.71.3Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceNBSENeuBase TherapeuticsN/AN/AN/AN/ANEPTNeptune Wellness SolutionsN/AN/AN/AN/APHASPhaseBio PharmaceuticalsN/AN/AN/AN/AVYNEVYNE Therapeutics3.00Buy$7.38140.23% UpsideCurrent Analyst RatingsLatest NEPT, NBSE, VYNE, and PHAS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails2/29/2024VYNEVYNE TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.75(Data available from 3/29/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookNBSENeuBase TherapeuticsN/AN/AN/AN/A$11.04 per shareN/ANEPTNeptune Wellness Solutions$52.62M0.00N/AN/A($91.90) per share0.00PHASPhaseBio Pharmaceuticals$818K0.00N/AN/A($1.93) per share0.00VYNEVYNE Therapeutics$420K103.06N/AN/A$6.36 per share0.48Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateNBSENeuBase Therapeutics-$4.37M-$7.70N/A∞N/AN/A-99.74%-60.13%4/2/2024 (Estimated)NEPTNeptune Wellness Solutions-$60.46M-$106.72N/AN/AN/A-128.13%N/A-141.94%7/15/2024 (Estimated)PHASPhaseBio Pharmaceuticals-$131.07M-$2.13N/AN/AN/A-12,572.13%N/A-174.38%N/AVYNEVYNE Therapeutics-$28.45M-$7.04N/AN/AN/A-6,710.38%-77.46%-62.93%5/9/2024 (Estimated)Latest NEPT, NBSE, VYNE, and PHAS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails2/29/2024Q4 2023VYNEVYNE Therapeutics-$0.50-$0.20+$0.30-$0.20$0.15 million$0.08 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthNBSENeuBase TherapeuticsN/AN/AN/AN/AN/ANEPTNeptune Wellness SolutionsN/AN/AN/AN/AN/APHASPhaseBio PharmaceuticalsN/AN/AN/AN/AN/AVYNEVYNE TherapeuticsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioNBSENeuBase TherapeuticsN/A2.872.87NEPTNeptune Wellness SolutionsN/A0.230.10PHASPhaseBio PharmaceuticalsN/A0.470.47VYNEVYNE TherapeuticsN/A12.7312.73OwnershipInstitutional OwnershipCompanyInstitutional OwnershipNBSENeuBase Therapeutics12.37%NEPTNeptune Wellness Solutions14.44%PHASPhaseBio Pharmaceuticals49.02%VYNEVYNE Therapeutics83.78%Insider OwnershipCompanyInsider OwnershipNBSENeuBase Therapeutics13.90%NEPTNeptune Wellness Solutions5.10%PHASPhaseBio Pharmaceuticals9.90%VYNEVYNE Therapeutics1.80%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableNBSENeuBase Therapeutics373.73 million3.21 millionNot OptionableNEPTNeptune Wellness Solutions584.53 million4.30 millionNot OptionablePHASPhaseBio Pharmaceuticals6049.86 million44.92 millionNot OptionableVYNEVYNE Therapeutics1014.10 million13.85 millionNot OptionableNEPT, NBSE, VYNE, and PHAS HeadlinesSourceHeadlineShort Interest in VYNE Therapeutics Inc. (NASDAQ:VYNE) Drops By 63.4%americanbankingnews.com - March 29 at 3:40 AMAcne Treatment Market Poised for Substantial Growth, Anticipated to Reach USD 16.2 Billion by 2032pharmiweb.com - March 28 at 12:46 PMVYNE Therapeutics (NASDAQ:VYNE) Stock Price Up 3.9%americanbankingnews.com - March 23 at 1:48 AMVYNE Therapeutics to Participate in the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conferencefinance.yahoo.com - March 19 at 9:08 AMVYNE Therapeutics to Participate in the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conferenceglobenewswire.com - March 19 at 8:00 AMHere's Why VYNE Therapeutics Inc. (VYNE) Is a Great 'Buy the Bottom' Stock Nowzacks.com - March 13 at 10:56 AMWhat Makes VYNE Therapeutics Inc. (VYNE) a New Buy Stockzacks.com - March 8 at 1:01 PMWall Street Breakfast Podcast: NYCB Gets $1B Investment Boostseekingalpha.com - March 7 at 8:21 AMVYNE Therapeutics Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lagfinance.yahoo.com - March 3 at 8:59 AMBuy Rating on VYNE Therapeutics: Strong Financials and Promising Clinical Developmentsmarkets.businessinsider.com - February 29 at 7:00 PMVYNE Therapeutics Inc.: VYNE Reports 2023 Fourth Quarter and Year-End Financial Results and Provides Business Updatefinanznachrichten.de - February 29 at 10:04 AMVYNE Reports 2023 Fourth Quarter and Year-End Financial Results and Provides Business Updateglobenewswire.com - February 29 at 8:00 AMVYNE Therapeutics to Present Results of the Phase 1b Trial for VYN201 at the 2024 Global Vitiligo Foundation Annual Scientific Symposiumfinance.yahoo.com - February 27 at 8:06 AMVYNE Therapeutics to Present Results of the Phase 1b Trial for VYN201 at the 2024 Global Vitiligo Foundation Annual Scientific Symposiumglobenewswire.com - February 27 at 8:00 AMVYNE Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conferencefinance.yahoo.com - February 21 at 8:16 AMVYNE Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conferenceglobenewswire.com - February 21 at 8:00 AMFavourable Signals For VYNE Therapeutics: Numerous Insiders Acquired Stockfinance.yahoo.com - February 2 at 7:18 AMBuy Rating for VYNE Therapeutics Backed by Promising Vitiligo Drug Trial Resultsmarkets.businessinsider.com - January 10 at 4:27 PMPrurigo Nodularis Treatment Market Forecasts Surpassing US$ 930.9 Million by 2033-FMI Studyfmiblog.com - January 4 at 12:32 AMVYNE Therapeutics Appoints Christine Borowski, Ph.D., to its Board of Directorsfinance.yahoo.com - January 3 at 9:29 AMInvesting in VYNE Therapeutics Inc [VYNE]: What You Must Knowknoxdaily.com - January 1 at 10:15 AMVYNE Therapeutics says director Lepore buys 13K shares in comsn.com - November 20 at 3:25 PMCormorant Asset Management, LP Acquires New Stake in VYNE Therapeutics Incfinance.yahoo.com - November 14 at 5:53 PMVYNE Therapeutics files to sell 36.27M shares for holdersmsn.com - November 13 at 5:35 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsNeuBase TherapeuticsNASDAQ:NBSENeuBase Therapeutics, Inc., a preclinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders, and cancer and oncology applications. Its pipeline includes NT0100 for Huntington's disease; NT0200 for myotonic dystrophy type 1; and NT0300 treatment targets the mutated KRAS gene. NeuBase Therapeutics, Inc. is headquartered in Pittsburgh, Pennsylvania.Neptune Wellness SolutionsNASDAQ:NEPTNeptune Wellness Solutions Inc., a health and wellness products company, specializes in the extraction, purification and formulation of cannabis products, as well as other specialty ingredients, such as MaxSimil, a patented ingredient that enhances the absorption of lipid-based nutraceuticals, and various other marine and seed oils. Its custom formulations are available in various delivery forms, such as softgels, liquid solutions, nutritional emulsions, and chewables. Neptune Wellness Solutions Inc. was founded in 1998 and is headquartered in Laval, Canada. PhaseBio PharmaceuticalsNASDAQ:PHASPhaseBio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapies for cardiovascular diseases. The firm's pipeline includes: bentracimab (PB2452), a novel reversal agent for the antiplatelet therapy ticagrelor, pemziviptadil (PB1046), a once-weekly vasoactive intestinal peptide receptor agonist for the treatment of pulmonary arterial hypertension, and PB6440, an oral agent for the treatment of resistant hypertension. The company was founded by Ashutosh Chilkoti and Clay Bernardin Thorp in January 2002 and is headquartered in Malvern, PA.VYNE TherapeuticsNASDAQ:VYNEVYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan-BET inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule bromodomain and extra-terminal inhibitor for the treatment of immuno-inflammatory indications; and FMX114, a combination gel formation of tofacitinib and fingolimod, which is in Phase IIa preclinical trial for the treatment of mild-to-moderate atopic dermatitis. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.